A serial entrepreneur having founded and co-founded more than 10 companies. He has been active in the biotechnology industry for over 25 years and has been leading the discovery and routine adoption of important blood biomarkers, as well as the development of drug candidates for critical care diseases. He holds a Ph.D. in Biochemistry from the Technical University Berlin. He is an inventor or co-inventor of more than 100 Patent families and has authored and co-authored over 200 peer-reviewed scientific publications. Dr. Bergmann founded 4TEEN4 Pharmaceuticals GmbH, Adrenomed AG, and SphingoTec GmbH, which are all located in Hennigsdorf. The companies are devoted to the development of blood-based diagnostic methods for prediction, prevention, intervention strategies, and early treatment of diseases in the cardiovascular, critical care, and acute care fields. Today´s diagnostic standard in sepsis, Procalcitonin (PCT), was developed under his supervision as Chief Research Officer and co-founder at B.R.A.H.M.S AG. The company was successfully sold to Thermo Fisher Scientific Inc. for 480 USD in 2009.

More than 13 years of experience in R&D of small molecule and antibody therapies as well as biomarker development. She is an author of more than 30 peer-reviewed scientific publications and a recipient of over 7 awards, including the prestigious Ernst-Eckhard-Koch Prize in 2013 and the Ph.D. Thesis Award from the German Biochemistry and Molecular Biology Society. She graduated with a Summa Cum Lauda from the University of Göttingen/Max Planck Institute for Biophysical Chemistry, Göttingen, and worked as a guest scientist for the Guangzhou Institute of Biomedicine and Health in China and EMBL, Grenoble in France. Dr. Karine Bourgeois works in close contact with intensivists and Key Opinion Leaders in Europe and America, leading the biomarker research and the drug development at 4TEEN4 Pharmaceuticals GmbH.